The Federal Trade Commission's antitrust lawsuit against Amazon will proceed, though some claims have been dropped, following a ruling from a federal district judge.
A federal judge in Seattle granted in part, and denied in part, Amazon's motion to dismiss the U.
Amazon won partial dismissal of an FTC lawsuit alleging illegal monopoly practices. The FTC accused Amazon of stifling competition by coercing sellers to use its service.
The Federal Trade Commission (FTC) on Monday cleared Chevron's (CVX) $53 billion acquisition of Hess (HES), but barred Hess CEO John Hess from joining Chevron's board, citing concerns about his previous communications with Organization of Petroleum Exporting Countries (OPEC) officials.
The FTC on Monday alleged that John Hess encouraged senior officials at OPEC to draw down inventories, which would result in higher oil prices. Hess Corp. and Chevron have agreed that they will not appoint Hess to the board in order to facilitate the completion of the merger.
The U.S. Federal Trade Commission allowed Chevron's $53 billion purchase of Hess Corp on Monday, in an order that barred Hess CEO John Hess from Chevron's board.
John Hess would be prevented from Chevron's board as part of deal for antitrust approval of a Hess-Chevron merger.
The Federal Trade Commission is cracking down on "automation" companies that launch and manage online businesses on behalf of customers in exchange for an upfront investment. The latest case targets Ascend Ecom, which ran an e-commerce money-making scheme, primarily on Amazon.
The U.S. Federal Trade Commission is expected to greenlight U.S. oil producer Chevron's purchase of Hess as soon as this week, two people familiar with the matter said, leaving Exxon Mobil's challenge to the $53 billion deal as its final hurdle.
Pharmacy-benefit managers owned by CVS, Cigna and UnitedHealth “artificially inflated” prices for lifesaving medications, regulator alleges.
The US Federal Trade Commission is accusing units of CVS, Cigna, and UnitedHealth of engaging in illegal rebate programs that drove up the price of insulin. Federal Trade Commission Office of Public Affairs Director Douglas Farrar discusses the lawsuit against the pharmacy benefits managers.
The Federal Trade Commission on Friday sued three large U.S. health companies that negotiate insulin prices, arguing the drug middlemen boost their profits while "artificially" inflating costs for patients. The suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group's Optum Rx, CVS Health's Caremark and Cigna's Express Scripts, and their affiliated group purchasing organizations.